{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:59:46Z","timestamp":1792187986441,"version":"4.4.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00277-023-05426-9","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T11:02:30Z","timestamp":1693825350000},"page":"1513-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Krecak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Lucijanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"5","key":"5426_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11899-022-00670-8","volume":"17","author":"I Krecak","year":"2022","unstructured":"Krecak I, Lucijanic M, Verstovsek S (2022) Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep 17(5):155\u2013169. https:\/\/doi.org\/10.1007\/s11899-022-00670-8","journal-title":"Curr Hematol Malig Rep"},{"key":"5426_CR2","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm 2015:102476. https:\/\/doi.org\/10.1155\/2015\/102476","journal-title":"Mediators Inflamm"},{"key":"5426_CR3","doi-asserted-by":"publisher","unstructured":"Holik H, Kre\u010dak I, Lucijani\u0107 M, Samard\u017ei\u0107 I, Pilipac D, Vu\u010dini\u0107 Ljubi\u010di\u0107 I, Coha B, Kitter Pipi\u0107 A, Mi\u0161ki\u0107 B, Zupan\u010di\u0107-\u0160alek S (2023) Hip and knee osteoarthritis in patients with chronic myeloproliferative neoplasms: a cross-sectional study. Life (Basel) 13(6). https:\/\/doi.org\/10.3390\/life13061388","DOI":"10.3390\/life13061388"},{"issue":"10","key":"5426_CR4","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1080\/10428194.2017.1296146","volume":"58","author":"M Lucijanic","year":"2017","unstructured":"Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Aralica G, Gecek I, Pejsa V, Kusec R (2017) Heat shock protein 27 (HSP27\/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. Leuk Lymphoma 58(10):2497\u20132500. https:\/\/doi.org\/10.1080\/10428194.2017.1296146","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5426_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/m17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317\u2013325. https:\/\/doi.org\/10.7326\/m17-0028","journal-title":"Ann Intern Med"},{"key":"5426_CR6","doi-asserted-by":"publisher","unstructured":"Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27002","DOI":"10.1002\/ajh.27002"},{"issue":"11","key":"5426_CR7","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369. https:\/\/doi.org\/10.1038\/bcj.2015.94","journal-title":"Blood Cancer J"},{"issue":"5","key":"5426_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/17474086.2023.2199151","volume":"16","author":"I Krecak","year":"2023","unstructured":"Krecak I, Skelin M, Verstovsek S (2023) Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Rev Hematol 16(5):305\u2013316. https:\/\/doi.org\/10.1080\/17474086.2023.2199151","journal-title":"Expert Rev Hematol"},{"issue":"26","key":"5426_CR9","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"issue":"2","key":"5426_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","volume":"10","author":"P Guglielmelli","year":"2020","unstructured":"Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T (2020) Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J 10(2):21. https:\/\/doi.org\/10.1038\/s41408-020-0289-2","journal-title":"Blood Cancer J"},{"issue":"4","key":"5426_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000514347","volume":"44","author":"I Kre\u010dak","year":"2021","unstructured":"Kre\u010dak I, Mori\u0107 Peri\u0107 M, Zekanovi\u0107 I, Holik H, Coha B, Gveri\u0107-Kre\u010dak V, Lucijani\u0107 M (2021) No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera. Oncol Res Treat 44(4):201\u2013203. https:\/\/doi.org\/10.1159\/000514347","journal-title":"Oncol Res Treat"},{"issue":"10","key":"5426_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1159\/000509376","volume":"43","author":"S Mancuso","year":"2020","unstructured":"Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F, Perez A, Bono M, Russo A, Siragusa S (2020) Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat 43(10):526\u2013530. https:\/\/doi.org\/10.1159\/000509376","journal-title":"Oncol Res Treat"},{"issue":"12","key":"5426_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","volume":"7","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7(12):662. https:\/\/doi.org\/10.1038\/s41408-017-0035-6","journal-title":"Blood Cancer J"},{"issue":"1","key":"5426_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.17130","volume":"193","author":"AL S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, Hasselbalch HC (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 193(1):83\u201392. https:\/\/doi.org\/10.1111\/bjh.17130","journal-title":"Br J Haematol"},{"issue":"5","key":"5426_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00277-021-04431-0","volume":"100","author":"I Kre\u010dak","year":"2021","unstructured":"Kre\u010dak I, Holik H, Coha B, Peri\u0107 MM, Zekanovi\u0107 I, Kre\u010dak MV, Gveri\u0107-Kre\u010dak V, Lucijani\u0107 M (2021) Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera. Ann Hematol 100(5):1335\u20131336. https:\/\/doi.org\/10.1007\/s00277-021-04431-0","journal-title":"Ann Hematol"},{"issue":"5","key":"5426_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/ejh.12517","volume":"95","author":"D Lekovic","year":"2015","unstructured":"Lekovic D, Gotic M, Sefer D, Mitrovic-Ajtic O, Cokic V, Milic N (2015) Predictors of survival and cause of death in patients with essential thrombocythemia. Eur J Haematol 95(5):461\u2013466. https:\/\/doi.org\/10.1111\/ejh.12517","journal-title":"Eur J Haematol"},{"issue":"2","key":"5426_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11239-022-02751-0","volume":"55","author":"C Furuya","year":"2023","unstructured":"Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N (2023) Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis 55(2):263\u2013272. https:\/\/doi.org\/10.1007\/s11239-022-02751-0","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"5426_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12032-014-0231-1","volume":"31","author":"D Lekovic","year":"2014","unstructured":"Lekovic D, Gotic M, Milic N, Miljic P, Mitrovic M, Cokic V, Elezovic I (2014) The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Med Oncol 31(10):231. https:\/\/doi.org\/10.1007\/s12032-014-0231-1","journal-title":"Med Oncol"},{"issue":"1","key":"5426_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clml.2018.08.020","volume":"19","author":"I Horvat","year":"2019","unstructured":"Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B (2019) Influence of blood count, cardiovascular risks, inherited thrombophilia, and JAK2 V617F burden allele on type of thrombosis in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 19(1):53\u201363. https:\/\/doi.org\/10.1016\/j.clml.2018.08.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"5426_CR20","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021\u20133023. https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"},{"issue":"2","key":"5426_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/ejh.12307","volume":"93","author":"V Buxhofer-Ausch","year":"2014","unstructured":"Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, M\u00fcllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H (2014) Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol 93(2):103\u2013111. https:\/\/doi.org\/10.1111\/ejh.12307","journal-title":"Eur J Haematol"},{"issue":"2","key":"5426_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/10715762.2013.860225","volume":"48","author":"T Rusak","year":"2014","unstructured":"Rusak T, Misztal T, Piszcz J, Tomasiak M (2014) Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. Free Radic Res 48(2):230\u2013238. https:\/\/doi.org\/10.3109\/10715762.2013.860225","journal-title":"Free Radic Res"},{"issue":"16","key":"5426_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/bf01733828","volume":"63","author":"W Zidek","year":"1985","unstructured":"Zidek W, Tenschert W, Karoff C, Vetter H (1985) Treatment of resistant hypertension by phlebotomy. Klin Wochenschr 63(16):762\u2013764. https:\/\/doi.org\/10.1007\/bf01733828","journal-title":"Klin Wochenschr"},{"issue":"2","key":"5426_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11655-018-3009-2","volume":"25","author":"XJ Xiong","year":"2019","unstructured":"Xiong XJ, Wang PQ, Li SJ (2019) Blood-letting therapy for hypertension: a systematic review and meta-analysis of randomized controlled trials. Chin J Integr Med 25(2):139\u2013146. https:\/\/doi.org\/10.1007\/s11655-018-3009-2","journal-title":"Chin J Integr Med"},{"issue":"12","key":"5426_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11906-018-0900-0","volume":"20","author":"R Satou","year":"2018","unstructured":"Satou R, Penrose H, Navar LG (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep 20(12):100. https:\/\/doi.org\/10.1007\/s11906-018-0900-0","journal-title":"Curr Hypertens Rep"},{"issue":"7","key":"5426_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ajh\/hpaa044","volume":"33","author":"LG Sanchez-Lozada","year":"2020","unstructured":"Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, Borghi C, Piani F, Cara-Fuentes G, Bjornstad P, Lanaspa MA, Johnson RJ (2020) Uric acid and hypertension: an update with recommendations. Am J Hypertens 33(7):583\u2013594. https:\/\/doi.org\/10.1093\/ajh\/hpaa044","journal-title":"Am J Hypertens"},{"issue":"2","key":"5426_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/s0002-9343(98)00390-8","volume":"106","author":"DV Vlahakos","year":"1999","unstructured":"Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, Marathias KP (1999) Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 106(2):158\u2013164. https:\/\/doi.org\/10.1016\/s0002-9343(98)00390-8","journal-title":"Am J Med"},{"issue":"9","key":"5426_CR28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4161\/cbt.6.9.4568","volume":"6","author":"MM Vrsalovic","year":"2007","unstructured":"Vrsalovic MM, Pejsa V, Veic TS, Kolonic SO, Ajdukovic R, Haris V, Jaksic O, Kusec R (2007) Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status. Cancer Biol Ther 6(9):1434\u20131436. https:\/\/doi.org\/10.4161\/cbt.6.9.4568","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"5426_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-11-752600","volume":"129","author":"T Barbui","year":"2017","unstructured":"Barbui T, Masciulli A, Ghirardi A, Carobbio A (2017) ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood 129(9):1226\u20131227. https:\/\/doi.org\/10.1182\/blood-2016-11-752600","journal-title":"Blood"},{"issue":"15-16","key":"5426_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00508-021-01812-3","volume":"133","author":"I Kre\u010dak","year":"2021","unstructured":"Kre\u010dak I, Mori\u0107 Peri\u0107 M, Zekanovi\u0107 I, Holik H, Coha B, Gveri\u0107-Kre\u010dak V, Lucijani\u0107 M (2021) Beneficial effect of ACE inhibitors on kidney function in polycythemia vera. Wien Klin Wochenschr 133(15-16):808\u2013815. https:\/\/doi.org\/10.1007\/s00508-021-01812-3","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"5426_CR31","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00277-023-05305-3","volume":"102","author":"M Lucijanic","year":"2023","unstructured":"Lucijanic M, Veic P, Aric I, Tupek KM, Soric E, Sabljic A, Vlasac Glasnovic J, Stoos-Veic T, Krecak I, Kusec R (2023) Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time. Ann Hematol 102(7):1955\u20131956. https:\/\/doi.org\/10.1007\/s00277-023-05305-3","journal-title":"Ann Hematol"},{"key":"5426_CR32","doi-asserted-by":"publisher","unstructured":"Mulas O, Mola B, Costa A, Pittau F, Mantovani D, Dess\u00ec S, Fronteddu A, La Nasa G, Caocci G (2023) Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05417-w","DOI":"10.1007\/s00277-023-05417-w"},{"issue":"2","key":"5426_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/mbp.0000000000000427","volume":"25","author":"A Akdi","year":"2020","unstructured":"Akdi A, \u00d6zeke \u00d6, Karanfil M, Ertem AG, Yayla \u00c7, Demirta\u015f K, G\u00fcney T, \u00dcnal S, Sel\u00e7uk MT (2020) Diurnal rhythm of blood pressure in patients with polycythemia vera. Blood Press Monit 25(2):69\u201374. https:\/\/doi.org\/10.1097\/mbp.0000000000000427","journal-title":"Blood Press Monit"},{"issue":"7-8","key":"5426_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.20452\/pamw.15473","volume":"130","author":"K J\u00f3\u017awik-Plebanek","year":"2020","unstructured":"J\u00f3\u017awik-Plebanek K, Dobrowolski P, Lewandowski J, Narkiewicz K, Sikorska A, Si\u0144ski M, Eisenhofer G, Schmieder RE, Januszewicz M, Windyga J, Prejbisz A, Januszewicz A (2020) Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia vera. Pol Arch Intern Med 130(7-8):607\u2013614. https:\/\/doi.org\/10.20452\/pamw.15473","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"5426_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"2","key":"5426_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3960\/jslrt.52.85","volume":"52","author":"H Fujita","year":"2012","unstructured":"Fujita H, Hamaki T, Handa N, Ohwada A, Tomiyama J, Nishimura S (2012) Hypocholesterolemia in patients with polycythemia vera. J Clin Exp Hematop 52(2):85\u201389. https:\/\/doi.org\/10.3960\/jslrt.52.85","journal-title":"J Clin Exp Hematop"},{"issue":"4","key":"5426_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","volume":"99","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak I, Holik H, Mori\u0107-Peri\u0107 M, Zekanovi\u0107 I, Coha B, Gveri\u0107-Kre\u010dak V (2020) The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol 99(4):911\u2013912. https:\/\/doi.org\/10.1007\/s00277-020-03950-6","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"5426_CR38","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1182\/blood-2018-99-119272","volume":"132","author":"N Podoltsev","year":"2018","unstructured":"Podoltsev N, Zhu M, Wang R, Zeidan AM, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X (2018) Use of statins, survival and incidence of thrombosis among older adults with polycythemia vera: a population-based study. Blood 132(Supplement 1):3580\u20133580. https:\/\/doi.org\/10.1182\/blood-2018-99-119272","journal-title":"Blood"},{"key":"5426_CR39","doi-asserted-by":"publisher","unstructured":"Kristensen DT, \u00d8vlisen AK, Jakobsen LH, Severinsen MT, Hannig LH, Starklint J, Hils\u00f8e MH, Vallentin AP, Brabrand M, Hasselbalch HC, El-Galaly TC, Roug AS (2023) Use of statins and risk of myeloproliferative neoplasms \u2014 a Danish nationwide case-control study. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2023009784","DOI":"10.1182\/bloodadvances.2023009784"},{"issue":"12","key":"5426_CR40","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","volume":"99","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic M, Galusic D, Krecak I, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Kusec R (2020) Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Ann Hematol 99(12):2779\u20132785. https:\/\/doi.org\/10.1007\/s00277-020-04239-4","journal-title":"Ann Hematol"},{"issue":"3","key":"5426_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","volume":"112","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak I, Holik H, Martina MP, Zekanovi\u0107 I, Coha B, Gveri\u0107-Kre\u010dak V (2020) Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol 112(3):377\u2013384. https:\/\/doi.org\/10.1007\/s12185-020-02898-7","journal-title":"Int J Hematol"},{"issue":"4","key":"5426_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","volume":"38","author":"AS Christensen","year":"2014","unstructured":"Christensen AS, M\u00f8ller JB, Hasselbalch HC (2014) Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 38(4):490\u2013495. https:\/\/doi.org\/10.1016\/j.leukres.2014.01.014","journal-title":"Leuk Res"},{"issue":"11","key":"5426_CR43","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.3324\/haematol.2018.208876","volume":"104","author":"Y Fukuda","year":"2019","unstructured":"Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N (2019) Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 104(11):e506\u2013e509. https:\/\/doi.org\/10.3324\/haematol.2018.208876","journal-title":"Haematologica"},{"key":"5426_CR44","doi-asserted-by":"publisher","unstructured":"Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, G\u00f6thert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, H\u00e4nel M, Parmentier S, Bommer M et al (2021) Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN Bioregistry. Cancers (Basel) 13(16). https:\/\/doi.org\/10.3390\/cancers13164086","DOI":"10.3390\/cancers13164086"},{"key":"5426_CR45","doi-asserted-by":"publisher","unstructured":"Kre\u010dak I, Holik H, Mori\u0107 Peri\u0107 M, Zekanovi\u0107 I, Coha B, Lucijani\u0107 M (2022) Chronic kidney disease has a higher prevalence in polycythemia vera than in secondary polycythemia, a matched case\u2013control analysis. Indian J Hematol Blood Transfus. https:\/\/doi.org\/10.1007\/s12288-022-01624-z","DOI":"10.1007\/s12288-022-01624-z"},{"issue":"7","key":"5426_CR46","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease \u2014 a systematic review and meta-analysis. PloS One 11(7):e0158765. https:\/\/doi.org\/10.1371\/journal.pone.0158765","journal-title":"PloS One"},{"issue":"2","key":"5426_CR47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12288-021-01515-9","volume":"38","author":"I Kre\u010dak","year":"2022","unstructured":"Kre\u010dak I, Holik H, Lucijani\u0107 M (2022) The prevalence of simple kidney cysts in polycythemia vera and its clinical associations. Indian J Hematol Blood Transfus 38(2):429\u2013431. https:\/\/doi.org\/10.1007\/s12288-021-01515-9","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"5426_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/17474086.2022.2039117","volume":"15","author":"M Lucijanic","year":"2022","unstructured":"Lucijanic M, Krecak I, Kusec R (2022) Renal disease associated with chronic myeloproliferative neoplasms. Expert Rev Hematol 15(2):93\u201396. https:\/\/doi.org\/10.1080\/17474086.2022.2039117","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"5426_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ki.2011.147","volume":"80","author":"SM Said","year":"2011","unstructured":"Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D\u2019Agati VD, Nasr SH (2011) Myeloproliferative neoplasms cause glomerulopathy. Kidney Int 80(7):753\u2013759. https:\/\/doi.org\/10.1038\/ki.2011.147","journal-title":"Kidney Int"},{"issue":"12","key":"5426_CR50","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/modpathol.2015.117","volume":"28","author":"MP Alexander","year":"2015","unstructured":"Alexander MP, Nasr SH, Kurtin PJ, Casey ET, Hernandez LP, Fidler ME, Sethi S, Cornell LD (2015) Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Mod Pathol 28(12):1574\u20131583. https:\/\/doi.org\/10.1038\/modpathol.2015.117","journal-title":"Mod Pathol"},{"issue":"5","key":"5426_CR51","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/his.14282","volume":"78","author":"M B\u00fcttner-Herold","year":"2021","unstructured":"B\u00fcttner-Herold M, Sticht C, Wiech T, Porubsky S (2021) Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome\/myeloproliferative neoplasms. Histopathology 78(5):738\u2013748. https:\/\/doi.org\/10.1111\/his.14282","journal-title":"Histopathology"},{"issue":"5","key":"5426_CR52","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00428-021-03129-y","volume":"479","author":"F Person","year":"2021","unstructured":"Person F, Meyer SC, Hopfer H, Menter T (2021) Renal post-mortem findings in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Virchows Arch 479(5):1013\u20131020. https:\/\/doi.org\/10.1007\/s00428-021-03129-y","journal-title":"Virchows Arch"},{"issue":"7","key":"5426_CR53","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00277-023-05296-1","volume":"102","author":"H Holik","year":"2023","unstructured":"Holik H, Lucijanic M, Krecak I (2023) Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease. Ann Hematol 102(7):1963\u20131965. https:\/\/doi.org\/10.1007\/s00277-023-05296-1","journal-title":"Ann Hematol"},{"issue":"5","key":"5426_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/ejh.13845","volume":"109","author":"MK Larsen","year":"2022","unstructured":"Larsen MK, Skov V, Kjaer L, M\u00f8ller-Palacino NA, Pedersen RK, Andersen M, Ottesen JT, Cordua S, Poulsen HE, Dahl M, Knudsen TA, Eickhardt-Dalb\u00f8ge CS, Koschmieder S, Pedersen KM, \u00c7olak Y, Bojesen SE, Nordestgaard BG, Stiehl T, Hasselbalch HC, Ellervik C (2022) Clonal haematopoiesis of indeterminate potential and impaired kidney function\u2014a Danish general population study with 11\u2009years follow-up. Eur J Haematol 109(5):576\u2013585. https:\/\/doi.org\/10.1111\/ejh.13845","journal-title":"Eur J Haematol"},{"issue":"5","key":"5426_CR55","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1681\/asn.2021060774","volume":"33","author":"C Vlasschaert","year":"2022","unstructured":"Vlasschaert C, McNaughton AJM, Chong M, Cook EK, Hopman W, Kestenbaum B, Robinson-Cohen C, Garland J, Moran SM, Par\u00e9 G, Clase CM, Tang M, Levin A, Holden R, Rauh MJ, Lanktree MB (2022) Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 33(5):985\u2013995. https:\/\/doi.org\/10.1681\/asn.2021060774","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5426_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41375-021-01382-3","volume":"36","author":"AAZ Dawoud","year":"2022","unstructured":"Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP (2022) Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 36(2):507\u2013515. https:\/\/doi.org\/10.1038\/s41375-021-01382-3","journal-title":"Leukemia"},{"issue":"1","key":"5426_CR57","doi-asserted-by":"publisher","first-page":"e12657","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657. https:\/\/doi.org\/10.1002\/rth2.12657","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"5426_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"issue":"6","key":"5426_CR59","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db16-1250","volume":"66","author":"PM Trivedi","year":"2017","unstructured":"Trivedi PM, Graham KL, Scott NA, Jenkins MR, Majaw S, Sutherland RM, Fynch S, Lew AM, Burns CJ, Krishnamurthy B, Brodnicki TC, Mannering SI, Kay TW, Thomas HE (2017) Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes 66(6):1650\u20131660. https:\/\/doi.org\/10.2337\/db16-1250","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"5426_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13300-022-01277-1","volume":"13","author":"M Botana","year":"2022","unstructured":"Botana M, Escalada J, Merchante \u00c1, Reyes R, Rozas P (2022) Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther 13(Suppl 1):5\u201317. https:\/\/doi.org\/10.1007\/s13300-022-01277-1","journal-title":"Diabetes Ther"},{"key":"5426_CR61","doi-asserted-by":"publisher","unstructured":"Gangat N, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: impact on hemoglobin\/hematocrit levels and outcomes among 11 consecutive patients. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27048","DOI":"10.1002\/ajh.27048"},{"key":"5426_CR62","doi-asserted-by":"publisher","unstructured":"Gangat N, Alkhateeb H, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: a Mayo Clinic series of nine consecutive cases. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27034","DOI":"10.1002\/ajh.27034"},{"issue":"7","key":"5426_CR63","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.1002\/ajh.26933","volume":"98","author":"N Gangat","year":"2023","unstructured":"Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, Begna KH, Pardanani A, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol 98(7):E165\u2013e167. https:\/\/doi.org\/10.1002\/ajh.26933","journal-title":"Am J Hematol"},{"issue":"2","key":"5426_CR64","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1111\/ijlh.13716","volume":"44","author":"I Kre\u010dak","year":"2022","unstructured":"Kre\u010dak I, Zekanovi\u0107 I, Holik H, Mori\u0107 Peri\u0107 M, Coha B, Gveri\u0107-Kre\u010dak V (2022) Estimating plasma volume using the Strauss-derived formula may improve prognostication in polycythemia vera. Int J Lab Hematol 44(2):e69\u2013e71. https:\/\/doi.org\/10.1111\/ijlh.13716","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"5426_CR65","doi-asserted-by":"publisher","first-page":"020901","DOI":"10.11613\/bm.2023.020901","volume":"33","author":"M Lucijanic","year":"2023","unstructured":"Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, Perisa V, Peric MM, Zekanovic I, Kusec R (2023) Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. Biochem Med (Zagreb) 33(2):020901. https:\/\/doi.org\/10.11613\/bm.2023.020901","journal-title":"Biochem Med (Zagreb)"},{"issue":"8","key":"5426_CR66","doi-asserted-by":"publisher","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","volume":"154","author":"F Ismail-Beigi","year":"2011","unstructured":"Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154(8):554\u2013559. https:\/\/doi.org\/10.7326\/0003-4819-154-8-201104190-00007","journal-title":"Ann Intern Med"},{"key":"5426_CR67","doi-asserted-by":"publisher","unstructured":"Ren Q, Lv X, Yang L, Yue J, Luo Y, Zhou L, Meng S, Yang S, Puchi B, Zhou X, Ji L (2020) Erythrocytosis and performance of HbA1c in detecting diabetes on an oxygen-deficient plateau: a population-based study. J Clin Endocrinol Metab 105(4). https:\/\/doi.org\/10.1210\/clinem\/dgaa001","DOI":"10.1210\/clinem\/dgaa001"},{"issue":"7","key":"5426_CR68","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/diacare.20.7.1211","volume":"20","author":"J Karsegard","year":"1997","unstructured":"Karsegard J, Wicky J, Mensi N, Caulfield A, Philippe J (1997) Spurious glycohemoglobin values associated with hydroxyurea treatment. Diabetes Care 20(7):1211\u20131212. https:\/\/doi.org\/10.2337\/diacare.20.7.1211","journal-title":"Diabetes Care"},{"issue":"1","key":"5426_CR69","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12885-021-08439-7","volume":"21","author":"SF Christensen","year":"2021","unstructured":"Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL (2021) Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer 21(1):691. https:\/\/doi.org\/10.1186\/s12885-021-08439-7","journal-title":"BMC Cancer"},{"issue":"1","key":"5426_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.12684","volume":"97","author":"A Lindholm S\u00f8rensen","year":"2016","unstructured":"Lindholm S\u00f8rensen A, Hasselbalch HC (2016) Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol 97(1):63\u201369. https:\/\/doi.org\/10.1111\/ejh.12684","journal-title":"Eur J Haematol"},{"issue":"1","key":"5426_CR71","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1097\/hs9.0000000000000327","volume":"4","author":"AS Duncombe","year":"2020","unstructured":"Duncombe AS, Anderson LA, James G, de Vocht F, Fritschi L, Mesa R, Clarke M, McMullin MF (2020) Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Hemasphere 4(1):e327. https:\/\/doi.org\/10.1097\/hs9.0000000000000327","journal-title":"Hemasphere"},{"key":"5426_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1\u201311. https:\/\/doi.org\/10.1016\/j.ejim.2020.07.006","journal-title":"Eur J Intern Med"},{"issue":"6","key":"5426_CR73","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ckj\/sfaa236","volume":"13","author":"G Gonzalez-Martin","year":"2020","unstructured":"Gonzalez-Martin G, Cano J, Carriazo S, Kanbay M, Perez-Gomez MV, Fernandez-Prado R, Ortiz A (2020) The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality. Clin Kidney J 13(6):936\u2013947. https:\/\/doi.org\/10.1093\/ckj\/sfaa236","journal-title":"Clin Kidney J"},{"issue":"10359","key":"5426_CR74","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/s0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM (2022) Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10359):1195\u20131205. https:\/\/doi.org\/10.1016\/s0140-6736(22)01657-9","journal-title":"Lancet"},{"issue":"3","key":"5426_CR75","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0049-0172(76)90026-3","volume":"5","author":"T Yu","year":"1976","unstructured":"Yu T, Weinreb N, Wittman R, Wasserman LR (1976) Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum 5(3):247\u2013256. https:\/\/doi.org\/10.1016\/0049-0172(76)90026-3","journal-title":"Semin Arthritis Rheum"},{"key":"5426_CR76","doi-asserted-by":"publisher","unstructured":"Krecak I, Lucijanic M, Gveric-Krecak V, Durakovic N (2020) Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2020.1731503","DOI":"10.1080\/10428194.2020.1731503"},{"issue":"3-4","key":"5426_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00508-020-01802-x","volume":"134","author":"M Lucijanic","year":"2022","unstructured":"Lucijanic M, Krecak I, Galusic D, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Pejsa V, Kusec R (2022) Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis. Wien Klin Wochenschr 134(3-4):97\u2013103. https:\/\/doi.org\/10.1007\/s00508-020-01802-x","journal-title":"Wien Klin Wochenschr"},{"key":"5426_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/vhrm.S168946","volume":"15","author":"S Carbone","year":"2019","unstructured":"Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ (2019) Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 15:89\u2013100. https:\/\/doi.org\/10.2147\/vhrm.S168946","journal-title":"Vasc Health Risk Manag"},{"key":"5426_CR79","doi-asserted-by":"publisher","unstructured":"Christensen SF, Scherber RM, Brochmann N, Goros M, Gelfond J, Andersen CL, Flachs EM, Mesa R (2020) Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association. Cancers (Basel) 12(8). https:\/\/doi.org\/10.3390\/cancers12082202","DOI":"10.3390\/cancers12082202"},{"issue":"3","key":"5426_CR80","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hon.2843","volume":"39","author":"G Benevolo","year":"2021","unstructured":"Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D\u2019Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L et al (2021) Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol 39(3):409\u2013418. https:\/\/doi.org\/10.1002\/hon.2843","journal-title":"Hematol Oncol"},{"issue":"7","key":"5426_CR81","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/oby.21863","volume":"25","author":"A Leiba","year":"2017","unstructured":"Leiba A, Duek A, Afek A, Derazne E, Leiba M (2017) Obesity and related risk of myeloproliferative neoplasms among israeli adolescents. Obesity (Silver Spring) 25(7):1187\u20131190. https:\/\/doi.org\/10.1002\/oby.21863","journal-title":"Obesity (Silver Spring)"},{"key":"5426_CR82","doi-asserted-by":"publisher","unstructured":"Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK (2023) Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel) 15(2). https:\/\/doi.org\/10.3390\/cancers15020485","DOI":"10.3390\/cancers15020485"},{"issue":"3","key":"5426_CR83","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10555-022-10046-2","volume":"41","author":"H BHL","year":"2022","unstructured":"BHL H, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM (2022) Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Rev 41(3):491\u2013515. https:\/\/doi.org\/10.1007\/s10555-022-10046-2","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"5426_CR84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15698\/cst2021.05.248","volume":"5","author":"XZ Liu","year":"2021","unstructured":"Liu XZ, Pedersen L, Halberg N (2021) Cellular mechanisms linking cancers to obesity. Cell Stress 5(5):55\u201372. https:\/\/doi.org\/10.15698\/cst2021.05.248","journal-title":"Cell Stress"},{"issue":"3-4","key":"5426_CR85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00508-018-1318-z","volume":"130","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R (2018) Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126\u2013133. https:\/\/doi.org\/10.1007\/s00508-018-1318-z","journal-title":"Wien Klin Wochenschr"},{"issue":"15","key":"5426_CR86","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/bloodadvances.2018018051","volume":"2","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD (2018) Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Adv 2(15):1980\u20131984. https:\/\/doi.org\/10.1182\/bloodadvances.2018018051","journal-title":"Blood Adv"},{"issue":"4","key":"5426_CR87","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00277-018-3569-1","volume":"98","author":"M Breccia","year":"2019","unstructured":"Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D\u2019Adda M, Crugnola M, Bosi C, Heidel F, Molica M et al (2019) Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Ann Hematol 98(4):889\u2013896. https:\/\/doi.org\/10.1007\/s00277-018-3569-1","journal-title":"Ann Hematol"},{"issue":"4","key":"5426_CR88","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00277-020-04243-8","volume":"100","author":"M Lucijanic","year":"2021","unstructured":"Lucijanic M, Galusic D, Soric E, Sedinic M, Cubela M, Huzjan Korunic R, Pejsa V, Kusec R (2021) Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol 100(4):1105\u20131106. https:\/\/doi.org\/10.1007\/s00277-020-04243-8","journal-title":"Ann Hematol"},{"issue":"13","key":"5426_CR89","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood.2019003050","volume":"135","author":"N Moll\u00e9","year":"2020","unstructured":"Moll\u00e9 N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM (2020) Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2\/STAT3. Blood 135(13):1062\u20131066. https:\/\/doi.org\/10.1182\/blood.2019003050","journal-title":"Blood"},{"issue":"3","key":"5426_CR90","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jjcc.2022.10.007","volume":"81","author":"O Leiva","year":"2023","unstructured":"Leiva O, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G (2023) Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation. J Cardiol 81(3):260\u2013267. https:\/\/doi.org\/10.1016\/j.jjcc.2022.10.007","journal-title":"J Cardiol"},{"key":"5426_CR91","doi-asserted-by":"publisher","unstructured":"Kre\u010dak I, Pivac L, Lucijani\u0107 M, Skelin M (2023) Polypharmacy, potentially inappropriate medications, and drug-to-drug interactions in patients with chronic myeloproliferative neoplasms. Biomedicines 11(5). https:\/\/doi.org\/10.3390\/biomedicines11051301","DOI":"10.3390\/biomedicines11051301"},{"key":"5426_CR92","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kre\u010dak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M (1925) Kiladjian J-J (2023) Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the Polycythemia Vera\u2014Advanced Integrated Models (PV-AIM) Project. Biomedicines 11(7)","DOI":"10.3390\/biomedicines11071925"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05426-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:03:29Z","timestamp":1712901809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5426"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05426-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}